CervoMed (CRVO) Interest & Investment Income (2022 - 2026)
CervoMed (CRVO) posted Interest & Investment Income of -$6024.0 for Q1 2026, down 102.5% sequentially from $240938.0 in Q4 2025, and up 82.78% YoY from -$3295.8 in Q1 2025.
CervoMed (CRVO) Interest & Investment Income (2022 - 2026) Analysis & Trends
CervoMed has reported Interest & Investment Income for 5 years, with the latest figure at -$6024.0 in Q1 2026.
- Quarterly Interest & Investment Income rose 82.78% year-over-year to -$6024.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $531695.0 (up 1.37% YoY) and the FY2025 annual result came in at $1.3 million, up 2278.84% from the prior year.
- Interest & Investment Income fell to -$6024.0 in Q1 2026 per CRVO's latest filing, from $240938.0 in the prior quarter.
- Over five years, Interest & Investment Income peaked at $646172.0 in Q3 2024 and troughed at -$66965.0 in Q4 2024.
- A 5-year average of $83964.9 and a median of $19613.0 in 2022 frame the typical range for Interest & Investment Income.
- The widest YoY moves for Interest & Investment Income: up 1255.6% in 2024, down 211.27% in 2024.
- Over 5 years, Interest & Investment Income stood at $32069.0 in 2022, then surged by 584.24% to $219430.0 in 2023, then sank by 130.52% to -$66965.0 in 2024, then jumped by 459.8% to $240938.0 in 2025, then tumbled by 102.5% to -$6024.0 in 2026.
- According to Business Quant data, Interest & Investment Income over the past three periods registered -$6024.0, $240938.0, and $318787.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | CervoMed | 26.64 Mn | 26.64 Mn | - | 104,897.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 104,897.00 |
| Mar 31, 2026 | -6,024.00 |
| Dec 31, 2025 | 240,938.00 |
| Sep 30, 2025 | 318,787.00 |
| Jun 30, 2025 | -22,006.00 |
| Mar 31, 2025 | -34,974.00 |
| Dec 31, 2024 | -66,965.00 |
| Sep 30, 2024 | 646,172.00 |
| Jun 30, 2024 | -19,702.00 |
| Dec 31, 2023 | 219,430.00 |
| Sep 30, 2023 | 47,667.00 |
| Jun 30, 2023 | 17,707.00 |
| Mar 31, 2023 | 35,404.00 |
| Dec 31, 2022 | 32,069.00 |
| Sep 30, 2022 | 21,519.00 |
| Jun 30, 2022 | -36,925.00 |
| Mar 31, 2022 | -49,658.00 |